PIN44 COST-EFFECTIVENESS ANALYSIS OF 1 YEAR PEGINTERFERON ALFA-2A VERSUS 4 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

Autor:	W Chen
Jazyk:	angličtina
Předmět:	HBEAG POSITIVE medicine.medical_specialty business.industry Health Policy Public Health Environmental and Occupational Health Entecavir Cost-effectiveness analysis Gastroenterology Chronic hepatitis Internal medicine medicine business medicine.drug Peginterferon alfa-2a
Zdroj:	Value in Health. (7):A438
ISSN:	1098-3015
DOI:	10.1016/S1098-3015(11)72842-X
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0739b02a419f68c4664ff4dbd537a43a Zobrazit plný text záznamu